[1]
|
WHO (2010) Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, World Health Organization, Geneva.
|
[2]
|
Desjeux, P. (2004) Leishmaniasis: Current situation and new perspectives. Comparative Immunology, Microbiology & Infectious Diseases, 27, 305-318.
doi:10.1016/j.cimid.2004.03.004
|
[3]
|
WHO (2004) TDR—Tropical disease research. World Health Organization, Geneva.
|
[4]
|
Mitropoulos, P., Konidas, P. and Durkin-Konidas, M. (2010) New World cutaneous leishmaniasis: Updated review of current and future diagnosis and treatment. Journal of the American Academy of Dermatology, 63, 309322. doi:10.1016/j.jaad.2009.06.088
|
[5]
|
Santos, D.O., Coutinho, C.E., Madeira, M.F., Bottino, C.G., Vieira, R.T., Nascimento, S.B., Bernardino, A., Bourguignon, S.C., Corte-Real, S., Pinho, R.T., Rodrigues, C.R. and Castro, H.C. (2008) Leishmaniasis treatment—A challenge that remains: A review. Parasitology Research, 103, 1-10. doi:10.1007/s00436-008-0943-2
|
[6]
|
Croft, S.L., Sundar, S. and Fairlamb, A.H. (2006) Drug resistance in leishmaniasis. Clinical Microbiology Reviews, 19, 111-126. doi:10.1128/CMR.19.1.111-126.2006
|
[7]
|
Croft, S.L., Seifert, K. and Yardley, V. (2006) Current scenario of drug development for leishmaniasis. Indian Journal of Medical Research, 123, 399-410.
|
[8]
|
Frezard, F., Demicheli, C. and Ribeiro, R.R. (2009) Pentavalent antimonials: New perspectives for old drugs. Molecules, 14, 2317-2336.
doi:10.3390/molecules14072317
|
[9]
|
Haldar, A.K., Sen, P. and Roy, S. (2011) Use of antimony in the treatment of leishmaniasis: Current status and future directions. Molecular Biology International, 2011, 1-23. doi:10.4061/2011/571242
|
[10]
|
Bray, P.G., Barrett, M.P., Ward, S.A. and de Koning, H.P. (2003) Pentamidine uptake and resistance in pathogenic protozoa: Past, present and future. Trends in Parasitology, 19, 232-239. doi:10.1016/S1471-4922(03)00069-2
|
[11]
|
Croft, S.L., Barrett, M.P. and Urbina, J.A. (2005) Chemotherapy of trypanosomiases and leishmaniasis. Trends in Parasitology, 21, 508-512.
doi:10.1016/j.pt.2005.08.026
|
[12]
|
Paila, Y.D., Saha, B. and Chattopadhyay, (2010) A. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages. Biochemical and Biophysical Research Communications, 399, 429-433.
doi:10.1016/j.bbrc.2010.07.099
|
[13]
|
Newman, D.J. and Cragg, G.M. (2007) Natural products as sources of new drugs over the last 25 years. Journal of Natural Products, 70, 461-477.
doi:10.1021/np068054v
|
[14]
|
Harvey, A.L. (2008) Natural products in drug discovery. Drug Discovery Today, 13, 894-901.
doi:10.1016/j.drudis.2008.07.004
|
[15]
|
Rocha, L.G., Almeida, J.R., Macedo, R.O. and BarbosaFilho, J.M. (2005) A review of natural products with antileishmanial activity. Phytomedicine, 12, 514-535.
doi:10.1016/j.phymed.2003.10.006
|
[16]
|
Mishra, B.B., Singh, R.K., Srivastava, A., Tripathi, V.J. and Tiwari, V.K. (2009) Fighting against leishmaniasis: search of alkaloids as future true potential anti-leishmanial agents. Mini Reviews in Medicinal Chemistry, 9, 107123. doi:10.2174/138955709787001758
|
[17]
|
de Carvalho, P.B. and Ferreira, E.I. (2001) Leishmaniasis phytotherapy. Nature’s leadership against an ancient disease. Fitoterapia, 72, 599-618.
doi:10.1016/S0367-326X(01)00301-X
|
[18]
|
Coy Barrera, C.A., Coy Barrera, E.D., Granados Falla, D.S., Delgado Murcia, G. and Cuca Suarez, L.E. (2011) Seco-limonoids and quinoline alkaloids from Raputia heptaphylla and their antileishmanial activity. Chemical & Pharmaceutical Bulletin, 59, 855-859.
doi:10.1248/cpb.59.855
|
[19]
|
Handman, E. (1999) Cell biology of Leishmania. Advances in Parasitology, 44, 1-39.
doi:10.1016/S0065-308X(08)60229-8
|
[20]
|
Basu, M.K. and Ray, M. (2005) Macrophage and Leishmania: An unacceptable coexistence. Critical Reviews in Microbiology, 31, 145-154.
doi:10.1080/10408410591005101
|
[21]
|
Rosas, L.V. (2005) Phytochemistry, chemosystematic and searching of new antichagasic and antileishmaniasis drugs: Study of Raputia praetermissa (Rutaceae). Tese (Doutorado), Universidade Federal de S?o Carlos, S?o Carlos.
|
[22]
|
Pulido, S.A., Munoz, D.L., Restrepo, A.M., Mesa, C.V., Alzate, J.F., Velez, I.D. and Robledo, S.M. (2012) Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs. Acta Tropica, 122, 36-45. doi:10.1016/j.actatropica.2011.11.015
|
[23]
|
Strober, W. (1997) Trypan blue exclusion test of cell viability. In: Coligan, J.E., Krusbeek, A.M., Margulies, D.H., Shevach, E.M. and Strober, W., Eds, Current Protocols in Immunology, John Wiley & Sons, Inc., New York.
|
[24]
|
Buckner, F.S. and Wilson, A.J. (2005) Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. American Journal of Tropical Medicine and Hygiene, 72, 600-605.
|
[25]
|
O'Brien, J., Wilson, I., Orton, T. and Pognan, F. (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. European Journal of Biochemistry, 267, 5421-5426.
doi:10.1046/j.1432-1327.2000.01606.x
|
[26]
|
Chakravarty, J. and Sundar, S. (2010) Drug resistance in leishmaniasis. Journal of Global Infectious Diseases, 2, 167-176. doi:10.4103/0974-777X.62887
|
[27]
|
Bogdan, C. and Rollinghoff, M. (1999) How do protozoan parasites survive inside macrophages? Parasitology Today, 15, 22-28. doi:10.1016/S0169-4758(98)01362-3
|
[28]
|
Burchmore, R.J. and Barrett, M.P. (2001) Life in vacuoles--nutrient acquisition by Leishmania amastigotes. International Journal for Parasitology, 31, 1311-1320.
|
[29]
|
Mougneau, E., Bihl, F. and Glaichenhaus, N. (2011) Cell biology and immunology of Leishmania. Immunological Reviews, 240, 286-296.
doi:10.1111/j.1600-065X.2010.00983.x
|
[30]
|
El-On, J. (2009) Current status and perspectives of the immunotherapy of leishmaniasis. Israel Medical Association Journal, 11, 623-628.
|
[31]
|
Mansueto, P., Vitale, G., Di Lorenzo, G., Rini, G.B., Mansueto, S. and Cillari, E. (2007) Immunopathology of leishmaniasis: an update. International Journal of Immunopathology and Pharmacology, 20, 435-445.
|
[32]
|
Saha, P., Mukhopadhyay, D. and Chatterjee, M. (2011) Immunomodulation by chemotherapeutic agents against leishmaniasis. International Immunopharmacology, 11, 1668-1679. doi:10.1016/j.intimp.2011.08.002
|
[33]
|
Vermeersch, M., da Luz, R.I., Tote, K., Timmermans, J.P., Cos, P. and Maes, L. (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrobial Agents and Chemotherapy, 53, 3855-3859.
doi:10.1128/AAC.00548-09
|
[34]
|
De Muylder, G., Ang, K.K., Chen, S., Arkin, M.R., Engel, J.C. and McKerrow, J.H. (2011) A screen against Leishmania intracellular amastigotes: Comparison to a promastigote screen and identification of a host cell-specific hit. PLOS Neglected Tropical Diseases, 5, e1253.
doi:10.1371/journal.pntd.0001253
|
[35]
|
Shukla, A.K., Singh, B.K., Patra, S. and Dubey, V.K. (2010) Rational approaches for drug designing against leishmaniasis. Applied Biochemistry and Biotechnology, 160, 2208-2218. doi:10.1007/s12010-009-8764-z
|